Yanxian Ren
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yanxian Ren has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Heng Zhou
School of Public Health Yangzhou University 225009 Yangzhou P. R. China
4 shared publications Jin Li
School of Basic Medical Sciences & School of Public Health, Faculty of Medicine, Yangzhou University, Yangzhou, China
3 shared publications- Pengfei Yang
Key Laboratory of Space Radiobiology of Gansu Province & Key Laboratory of Heavy Ion Radiation Biology and Medicine, Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, China
3 shared publications - Wenbo Meng
Department of General Surgery, The First Hospital of Lanzhou University, No. 1 Donggang West Road, Lanzhou 730030, China
3 shared publications Chenghao Li
School of Traditional Chinese Medicine, Faculty of Medicine, Yangzhou University, Yangzhou, China
2 shared publications- Haining Li
Gansu Provincial Cancer Hospital, Gansu Provincial Academic Institute for Medical Sciences, Lanzhou, China
2 shared publications
Latest Publications
- Open Access
- 30 July 2026
- Published by Springer Nature in Cell Death Discovery
- Vol. 12 (1)
Mitophagy-dependent mitochondrial DNA release links ionizing radiation to immunogenic cell death in pancreatic cancer
Ionizing radiation (IR) elicits both cytotoxic and immunomodulatory effects, yet the precise link between mitochondrial remodeling and immunogenic cell death (ICD) remains elusive. Here, we report that IR triggers robust mitophagy in pancreatic cancer cells, marked by mitochondrial damage, Parkin/BNIP3 upregulation, and increased autophagic flux. In parallel, IR induces key hallmarks of ICD, including calreticulin exposure, HMGB1 translocation, and the release of ATP and IFN-β. Notably, genetic or pharmacological inhibition of mitophagy attenuated this immunogenic profile, whereas mitophagy induction amplified it. We further demonstrate that mitophagy triggers the cytosolic release of mitochondrial DNA (mtDNA) to activate immune signaling, which can be reversed by blocking mtDNA replication. In murine models, Parkin overexpression enhanced mitophagy and ICD marker expression, leading to reduced tumor burden and prolonged survival following irradiation. Collectively, our findings indicate that mtDNA leakage downstream of mitophagy links mitochondrial remodeling to radiation-induced ICD, suggesting that modulation of mitochondrial dynamics may represent a strategy to enhance both radiosensitivity and the immunogenic potential of radiotherapy in pancreatic cancer.
- 30 July 2026
- Published by Springer Nature in Cell Death Discovery
- Vol. 12 (1)
Open AccessMitophagy-dependent mitochondrial DNA release links ionizing radiation to immunogenic cell death in pancreatic cancer
Ionizing radiation (IR) elicits both cytotoxic and immunomodulatory effects, yet the precise link between mitochondrial remodeling and immunogenic cell death (ICD) remains elusive. Here, we report that IR triggers robust mitophagy in pancreatic cancer cells, marked by mitochondrial damage, Parkin/BNIP3 upregulation, and increased autophagic flux. In parallel, IR induces key hallmarks of ICD, including calreticulin exposure, HMGB1 translocation, and the release of ATP and IFN-β. Notably, genetic or pharmacological inhibition of mitophagy attenuated this immunogenic profile, whereas mitophagy induction amplified it. We further demonstrate that mitophagy triggers the cytosolic release of mitochondrial DNA (mtDNA) to activate immune signaling, which can be reversed by blocking mtDNA replication. In murine models, Parkin overexpression enhanced mitophagy and ICD marker expression, leading to reduced tumor burden and prolonged survival following irradiation. Collectively, our findings indicate that mtDNA leakage downstream of mitophagy links mitochondrial remodeling to radiation-induced ICD, suggesting that modulation of mitochondrial dynamics may represent a strategy to enhance both radiosensitivity and the immunogenic potential of radiotherapy in pancreatic cancer.
- Open Access
- 1 May 2026
- Published by AME Publishing Company in Translational Gastroenterology and Hepatology
- Vol. 11, 73
Enhancing future liver remnant hypertrophy: innovative preoperative strategies and emerging technologies
Major hepatectomy remains the only curative option for many primary and secondary liver malignancies, yet postoperative liver failure continues to limit resectability when the future liver remnant (FLR) is insufficient. Over recent decades, a spectrum of strategies has been developed to safely enlarge and optimize FLR volume and function. This review summarizes established and emerging approaches aimed at enhancing preoperative FLR hypertrophy. Conventional methods such as portal vein embolization (PVE) and portal vein ligation (PVL) remain first-line techniques, while associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) achieves rapid but riskier hypertrophy. Liver venous deprivation (LVD) and combined strategies—including transarterial chemoembolization (TACE) plus PVE or radioembolization—offer faster or dual oncologic-regenerative benefits with improved safety profiles. Innovative developments such as pharmacologic modulation [farnesoid X receptor (FXR), FGF19, THR-β, and GLP-1 agonists], growth factor delivery, and stem-cell-based therapies are emerging to enhance both volumetric and functional regeneration, particularly in steatotic or fibrotic livers. Advanced imaging and predictive technologies—such as 99mTc-mebrofenin hepatobiliary scintigraphy (HBS), four-dimensional (4D)-flow magnetic resonance imaging (MRI), and computed tomography (CT)-based radiomics—enable integrated volumetric-functional assessment and individualized surgical timing. Although PVE remains the benchmark, multimodal, patient-tailored strategies combining hemodynamic, pharmacologic, and cellular interventions, guided by functional imaging, are reshaping the landscape of hepatic surgery. Future randomized trials and translational studies are essential to define optimal algorithms, validate novel therapies, and safely extend curative resection to a broader population of patients with complex liver disease.
- 1 May 2026
- Published by AME Publishing Company in Translational Gastroenterology and Hepatology
- Vol. 11, 73
Open AccessEnhancing future liver remnant hypertrophy: innovative preoperative strategies and emerging technologies
Major hepatectomy remains the only curative option for many primary and secondary liver malignancies, yet postoperative liver failure continues to limit resectability when the future liver remnant (FLR) is insufficient. Over recent decades, a spectrum of strategies has been developed to safely enlarge and optimize FLR volume and function. This review summarizes established and emerging approaches aimed at enhancing preoperative FLR hypertrophy. Conventional methods such as portal vein embolization (PVE) and portal vein ligation (PVL) remain first-line techniques, while associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) achieves rapid but riskier hypertrophy. Liver venous deprivation (LVD) and combined strategies—including transarterial chemoembolization (TACE) plus PVE or radioembolization—offer faster or dual oncologic-regenerative benefits with improved safety profiles. Innovative developments such as pharmacologic modulation [farnesoid X receptor (FXR), FGF19, THR-β, and GLP-1 agonists], growth factor delivery, and stem-cell-based therapies are emerging to enhance both volumetric and functional regeneration, particularly in steatotic or fibrotic livers. Advanced imaging and predictive technologies—such as 99mTc-mebrofenin hepatobiliary scintigraphy (HBS), four-dimensional (4D)-flow magnetic resonance imaging (MRI), and computed tomography (CT)-based radiomics—enable integrated volumetric-functional assessment and individualized surgical timing. Although PVE remains the benchmark, multimodal, patient-tailored strategies combining hemodynamic, pharmacologic, and cellular interventions, guided by functional imaging, are reshaping the landscape of hepatic surgery. Future randomized trials and translational studies are essential to define optimal algorithms, validate novel therapies, and safely extend curative resection to a broader population of patients with complex liver disease.
- Open Access
- 29 June 2024
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 14 (9) , 3931-3948
Beyond ribosomal function: RPS6 deficiency suppresses cholangiocarcinoma cell growth by disrupting alternative splicing
- 29 June 2024
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 14 (9) , 3931-3948
Open AccessBeyond ribosomal function: RPS6 deficiency suppresses cholangiocarcinoma cell growth by disrupting alternative splicing
- 12 October 2023
- Published by Springer Nature in Cell Death & Differentiation
- Vol. 30 (11) , 2432-2445
Ionizing radiation-induced mitophagy promotes ferroptosis by increasing intracellular free fatty acids
Ferroptosis is a type of cell death characterized by the accumulation of intracellular iron and an increase in hazardous lipid peroxides. Ferroptosis and autophagy are closely related. Ionizing radiation is a frequently used cancer therapy to kill malignancies. We found that ionizing radiation induces both ferroptosis and autophagy and that there is a form of mutualism between the two processes. Ionizing radiation also causes lipid droplets to form in proximity to damaged mitochondria, which, through the action of mitophagy, results in the degradation of the peridroplet mitochondria by lysosomes and the consequent release of free fatty acids and a significant increase in lipid peroxidation, thus promoting ferroptosis. Ionizing radiation has a stronger, fatal effect on cells with a high level of mitophagy, and this observation suggests a novel strategy for tumor treatment.
- 12 October 2023
- Published by Springer Nature in Cell Death & Differentiation
- Vol. 30 (11) , 2432-2445
Ionizing radiation-induced mitophagy promotes ferroptosis by increasing intracellular free fatty acids
Ferroptosis is a type of cell death characterized by the accumulation of intracellular iron and an increase in hazardous lipid peroxides. Ferroptosis and autophagy are closely related. Ionizing radiation is a frequently used cancer therapy to kill malignancies. We found that ionizing radiation induces both ferroptosis and autophagy and that there is a form of mutualism between the two processes. Ionizing radiation also causes lipid droplets to form in proximity to damaged mitochondria, which, through the action of mitophagy, results in the degradation of the peridroplet mitochondria by lysosomes and the consequent release of free fatty acids and a significant increase in lipid peroxidation, thus promoting ferroptosis. Ionizing radiation has a stronger, fatal effect on cells with a high level of mitophagy, and this observation suggests a novel strategy for tumor treatment.
- Open Access
- 28 July 2023
- Published by Springer Nature in Cell Death Discovery
- Vol. 9 (1) , 1-12
Ionizing radiation triggers mitophagy to enhance DNA damage in cancer cells
Radiotherapy is an important cancer treatment strategy that causes DNA damage in tumor cells either directly or indirectly. Autophagy is a physiological process linked to DNA damage. Mitophagy is a form of autophagy, which specifically targets and eliminates impaired mitochondria, thereby upholding cellular homeostasis. However, the connection between DNA damage and mitophagy has yet to be fully elucidated. We found that mitophagy, as an upstream signal, increases ionizing radiation-induced DNA damage by downregulating or overexpressing key mitophagy proteins Parkin and BNIP3. Enhancing the basal level of mitophagy in conjunction with X-ray irradiation can potentially diminish cell cycle arrest at the G2/M phase, substantially elevate the accumulation of γ-H2AX, 53BP1, and PARP1 foci within the nucleus, augment DNA damage, and facilitate the demise of tumor cells. Consequently, this approach prolongs the survival of melanoma-bearing mice. The findings of this study are anticipated to offer a therapeutic approach for enhancing the therapeutic effectiveness of radiotherapy.
- 28 July 2023
- Published by Springer Nature in Cell Death Discovery
- Vol. 9 (1) , 1-12
Open AccessIonizing radiation triggers mitophagy to enhance DNA damage in cancer cells
Radiotherapy is an important cancer treatment strategy that causes DNA damage in tumor cells either directly or indirectly. Autophagy is a physiological process linked to DNA damage. Mitophagy is a form of autophagy, which specifically targets and eliminates impaired mitochondria, thereby upholding cellular homeostasis. However, the connection between DNA damage and mitophagy has yet to be fully elucidated. We found that mitophagy, as an upstream signal, increases ionizing radiation-induced DNA damage by downregulating or overexpressing key mitophagy proteins Parkin and BNIP3. Enhancing the basal level of mitophagy in conjunction with X-ray irradiation can potentially diminish cell cycle arrest at the G2/M phase, substantially elevate the accumulation of γ-H2AX, 53BP1, and PARP1 foci within the nucleus, augment DNA damage, and facilitate the demise of tumor cells. Consequently, this approach prolongs the survival of melanoma-bearing mice. The findings of this study are anticipated to offer a therapeutic approach for enhancing the therapeutic effectiveness of radiotherapy.
- Top Cited PapersOpen Access
- 25 October 2022
- Published by Springer Nature in Cell Death & Disease
- Vol. 13 (10) , 1-11
Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer with a prominent extracellular matrix (ECM) deposition and poor prognosis. High levels of ECM proteins derived from tumour cells reduce the efficacy of conventional cancer treatment paradigms and contribute to tumour progression and metastasis. As abundant tumour-promoting cells in the ECM, cancer-associated fibroblasts (CAFs) are promising targets for novel anti-tumour interventions. Nonetheless, related clinical trials are hampered by the lack of specific markers and elusive differences between CAF subtypes. Here, we review the origins and functional diversity of CAFs and show how they create a tumour-promoting milieu, focusing on the crosstalk between CAFs, tumour cells, and immune cells in the tumour microenvironment. Furthermore, relevant clinical advances and potential therapeutic strategies relating to CAFs are discussed.
- 25 October 2022
- Published by Springer Nature in Cell Death & Disease
- Vol. 13 (10) , 1-11
Top Cited PapersOpen AccessCancer-associated fibroblasts in pancreatic ductal adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer with a prominent extracellular matrix (ECM) deposition and poor prognosis. High levels of ECM proteins derived from tumour cells reduce the efficacy of conventional cancer treatment paradigms and contribute to tumour progression and metastasis. As abundant tumour-promoting cells in the ECM, cancer-associated fibroblasts (CAFs) are promising targets for novel anti-tumour interventions. Nonetheless, related clinical trials are hampered by the lack of specific markers and elusive differences between CAF subtypes. Here, we review the origins and functional diversity of CAFs and show how they create a tumour-promoting milieu, focusing on the crosstalk between CAFs, tumour cells, and immune cells in the tumour microenvironment. Furthermore, relevant clinical advances and potential therapeutic strategies relating to CAFs are discussed.